ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Recombinant Antihemophilic Factor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-13B12316
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Recombinant Antihemophilic Factor Industry Research Report Growth Trends and Competitive Analysis 2022 2028
BUY CHAPTERS

Recombinant Antihemophilic Factor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-13B12316
Report
September 2024
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Takeda
Bayer
CSL Limited
Pfizer Inc
Biogen
Octapharma AG
Novo Nordisk
Sanofi
SOBI

Recombinant Antihemophilic Factor - Market Size

The global market for Recombinant Antihemophilic Factor was estimated to be worth US$ 2152 million in 2023 and is forecast to a readjusted size of US$ 2994.2 million by 2030 with a CAGR of 4.8% during the forecast period 2024-2030

Recombinant Antihemophilic Factor - Market

Recombinant Antihemophilic Factor - Market

Recombinant antihemophilic factor works by temporarily raising levels of factor VIII in the blood to aid in clotting.
The market for recombinant antihemophilic factor has witnessed significant growth in recent years. This can be attributed to several factors, including the increasing prevalence of hemophilia, advancements in recombinant DNA technology, and improved access to healthcare services. Hemophilia is a genetic bleeding disorder that requires lifelong treatment with antihemophilic factors, such as factor VIII or factor IX. Recombinant antihemophilic factor, produced using recombinant DNA technology, offers advantages over plasma-derived products, including enhanced safety, reduced risk of infection transmission, and increased supply stability.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Antihemophilic Factor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant Antihemophilic Factor by region & country, by Type, and by Application.
The Recombinant Antihemophilic Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Antihemophilic Factor.
Market Segmentation

Scope of Recombinant Antihemophilic Factor - Market Report

Report Metric Details
Report Name Recombinant Antihemophilic Factor - Market
Forecasted market size in 2030 US$ 2994.2 million
CAGR 4.8%
Forecasted years 2024 - 2030
Segment by Type:
  • 200IU
  • 250IU
Segment by Application
  • Hospital
  • Pharmacy
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma, Novo Nordisk, Sanofi, Sobi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Recombinant Antihemophilic Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Recombinant Antihemophilic Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Recombinant Antihemophilic Factor in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Recombinant Antihemophilic Factor - Market size in 2030?

Ans: The Recombinant Antihemophilic Factor - Market size in 2030 will be US$ 2994.2 million.

Who are the main players in the Recombinant Antihemophilic Factor - Market report?

Ans: The main players in the Recombinant Antihemophilic Factor - Market are Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma, Novo Nordisk, Sanofi, Sobi

What are the Application segmentation covered in the Recombinant Antihemophilic Factor - Market report?

Ans: The Applications covered in the Recombinant Antihemophilic Factor - Market report are Hospital, Pharmacy

What are the Type segmentation covered in the Recombinant Antihemophilic Factor - Market report?

Ans: The Types covered in the Recombinant Antihemophilic Factor - Market report are 200IU, 250IU

Recommended Reports

Clotting Factors

Recombinant Proteins

Hemostasis & Bleeding

1 Market Overview
1.1 Recombinant Antihemophilic Factor Product Introduction
1.2 Global Recombinant Antihemophilic Factor Market Size Forecast
1.2.1 Global Recombinant Antihemophilic Factor Sales Value (2019-2030)
1.2.2 Global Recombinant Antihemophilic Factor Sales Volume (2019-2030)
1.2.3 Global Recombinant Antihemophilic Factor Sales Price (2019-2030)
1.3 Recombinant Antihemophilic Factor Market Trends & Drivers
1.3.1 Recombinant Antihemophilic Factor Industry Trends
1.3.2 Recombinant Antihemophilic Factor Market Drivers & Opportunity
1.3.3 Recombinant Antihemophilic Factor Market Challenges
1.3.4 Recombinant Antihemophilic Factor Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant Antihemophilic Factor Players Revenue Ranking (2023)
2.2 Global Recombinant Antihemophilic Factor Revenue by Company (2019-2024)
2.3 Global Recombinant Antihemophilic Factor Players Sales Volume Ranking (2023)
2.4 Global Recombinant Antihemophilic Factor Sales Volume by Company Players (2019-2024)
2.5 Global Recombinant Antihemophilic Factor Average Price by Company (2019-2024)
2.6 Key Manufacturers Recombinant Antihemophilic Factor Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Recombinant Antihemophilic Factor Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Recombinant Antihemophilic Factor
2.9 Recombinant Antihemophilic Factor Market Competitive Analysis
2.9.1 Recombinant Antihemophilic Factor Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Recombinant Antihemophilic Factor Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Antihemophilic Factor as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 200IU
3.1.2 250IU
3.2 Global Recombinant Antihemophilic Factor Sales Value by Type
3.2.1 Global Recombinant Antihemophilic Factor Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant Antihemophilic Factor Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant Antihemophilic Factor Sales Value, by Type (%) (2019-2030)
3.3 Global Recombinant Antihemophilic Factor Sales Volume by Type
3.3.1 Global Recombinant Antihemophilic Factor Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Recombinant Antihemophilic Factor Sales Volume, by Type (2019-2030)
3.3.3 Global Recombinant Antihemophilic Factor Sales Volume, by Type (%) (2019-2030)
3.4 Global Recombinant Antihemophilic Factor Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.2 Global Recombinant Antihemophilic Factor Sales Value by Application
4.2.1 Global Recombinant Antihemophilic Factor Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant Antihemophilic Factor Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant Antihemophilic Factor Sales Value, by Application (%) (2019-2030)
4.3 Global Recombinant Antihemophilic Factor Sales Volume by Application
4.3.1 Global Recombinant Antihemophilic Factor Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Recombinant Antihemophilic Factor Sales Volume, by Application (2019-2030)
4.3.3 Global Recombinant Antihemophilic Factor Sales Volume, by Application (%) (2019-2030)
4.4 Global Recombinant Antihemophilic Factor Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant Antihemophilic Factor Sales Value by Region
5.1.1 Global Recombinant Antihemophilic Factor Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant Antihemophilic Factor Sales Value by Region (2019-2024)
5.1.3 Global Recombinant Antihemophilic Factor Sales Value by Region (2025-2030)
5.1.4 Global Recombinant Antihemophilic Factor Sales Value by Region (%), (2019-2030)
5.2 Global Recombinant Antihemophilic Factor Sales Volume by Region
5.2.1 Global Recombinant Antihemophilic Factor Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Recombinant Antihemophilic Factor Sales Volume by Region (2019-2024)
5.2.3 Global Recombinant Antihemophilic Factor Sales Volume by Region (2025-2030)
5.2.4 Global Recombinant Antihemophilic Factor Sales Volume by Region (%), (2019-2030)
5.3 Global Recombinant Antihemophilic Factor Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Recombinant Antihemophilic Factor Sales Value, 2019-2030
5.4.2 North America Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Recombinant Antihemophilic Factor Sales Value, 2019-2030
5.5.2 Europe Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Recombinant Antihemophilic Factor Sales Value, 2019-2030
5.6.2 Asia Pacific Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Recombinant Antihemophilic Factor Sales Value, 2019-2030
5.7.2 South America Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Recombinant Antihemophilic Factor Sales Value, 2019-2030
5.8.2 Middle East & Africa Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant Antihemophilic Factor Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant Antihemophilic Factor Sales Value
6.2.1 Key Countries/Regions Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.2.2 Key Countries/Regions Recombinant Antihemophilic Factor Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.3.2 United States Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant Antihemophilic Factor Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.4.2 Europe Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant Antihemophilic Factor Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.5.2 China Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant Antihemophilic Factor Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.6.2 Japan Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant Antihemophilic Factor Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.7.2 South Korea Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant Antihemophilic Factor Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant Antihemophilic Factor Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant Antihemophilic Factor Sales Value, 2019-2030
6.9.2 India Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant Antihemophilic Factor Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Takeda
7.1.1 Takeda Company Information
7.1.2 Takeda Introduction and Business Overview
7.1.3 Takeda Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Takeda Recombinant Antihemophilic Factor Product Offerings
7.1.5 Takeda Recent Development
7.2 Bayer
7.2.1 Bayer Company Information
7.2.2 Bayer Introduction and Business Overview
7.2.3 Bayer Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Bayer Recombinant Antihemophilic Factor Product Offerings
7.2.5 Bayer Recent Development
7.3 CSL
7.3.1 CSL Company Information
7.3.2 CSL Introduction and Business Overview
7.3.3 CSL Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.3.4 CSL Recombinant Antihemophilic Factor Product Offerings
7.3.5 CSL Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Recombinant Antihemophilic Factor Product Offerings
7.4.5 Pfizer Recent Development
7.5 Biogen
7.5.1 Biogen Company Information
7.5.2 Biogen Introduction and Business Overview
7.5.3 Biogen Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Biogen Recombinant Antihemophilic Factor Product Offerings
7.5.5 Biogen Recent Development
7.6 Octapharma
7.6.1 Octapharma Company Information
7.6.2 Octapharma Introduction and Business Overview
7.6.3 Octapharma Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Octapharma Recombinant Antihemophilic Factor Product Offerings
7.6.5 Octapharma Recent Development
7.7 Novo Nordisk
7.7.1 Novo Nordisk Company Information
7.7.2 Novo Nordisk Introduction and Business Overview
7.7.3 Novo Nordisk Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Novo Nordisk Recombinant Antihemophilic Factor Product Offerings
7.7.5 Novo Nordisk Recent Development
7.8 Sanofi
7.8.1 Sanofi Company Information
7.8.2 Sanofi Introduction and Business Overview
7.8.3 Sanofi Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sanofi Recombinant Antihemophilic Factor Product Offerings
7.8.5 Sanofi Recent Development
7.9 Sobi
7.9.1 Sobi Company Information
7.9.2 Sobi Introduction and Business Overview
7.9.3 Sobi Recombinant Antihemophilic Factor Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Sobi Recombinant Antihemophilic Factor Product Offerings
7.9.5 Sobi Recent Development
8 Industry Chain Analysis
8.1 Recombinant Antihemophilic Factor Industrial Chain
8.2 Recombinant Antihemophilic Factor Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant Antihemophilic Factor Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant Antihemophilic Factor Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Takeda
Bayer
CSL Limited
Pfizer Inc
Biogen
Octapharma AG
Novo Nordisk
Sanofi
SOBI
List of Tables
    Table 1. Recombinant Antihemophilic Factor Market Trends
    Table 2. Recombinant Antihemophilic Factor Market Drivers & Opportunity
    Table 3. Recombinant Antihemophilic Factor Market Challenges
    Table 4. Recombinant Antihemophilic Factor Market Restraints
    Table 5. Global Recombinant Antihemophilic Factor Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Recombinant Antihemophilic Factor Revenue Market Share by Company (2019-2024)
    Table 7. Global Recombinant Antihemophilic Factor Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Recombinant Antihemophilic Factor Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Recombinant Antihemophilic Factor Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Recombinant Antihemophilic Factor Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Recombinant Antihemophilic Factor Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Recombinant Antihemophilic Factor
    Table 13. Global Recombinant Antihemophilic Factor Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Antihemophilic Factor as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Recombinant Antihemophilic Factor Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Recombinant Antihemophilic Factor Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Recombinant Antihemophilic Factor Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Recombinant Antihemophilic Factor Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Recombinant Antihemophilic Factor Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Recombinant Antihemophilic Factor Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Recombinant Antihemophilic Factor Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Recombinant Antihemophilic Factor Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Recombinant Antihemophilic Factor Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Recombinant Antihemophilic Factor Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Recombinant Antihemophilic Factor Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Recombinant Antihemophilic Factor Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Recombinant Antihemophilic Factor Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Recombinant Antihemophilic Factor Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Recombinant Antihemophilic Factor Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Recombinant Antihemophilic Factor Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Recombinant Antihemophilic Factor Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Recombinant Antihemophilic Factor Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Recombinant Antihemophilic Factor Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Recombinant Antihemophilic Factor Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Recombinant Antihemophilic Factor Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Recombinant Antihemophilic Factor Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Recombinant Antihemophilic Factor Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Recombinant Antihemophilic Factor Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Recombinant Antihemophilic Factor Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Recombinant Antihemophilic Factor Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Recombinant Antihemophilic Factor Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Recombinant Antihemophilic Factor Sales Value by Region (2019-2024) & (%)
    Table 44. Global Recombinant Antihemophilic Factor Sales Value by Region (2025-2030) & (%)
    Table 45. Global Recombinant Antihemophilic Factor Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Recombinant Antihemophilic Factor Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Recombinant Antihemophilic Factor Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Recombinant Antihemophilic Factor Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Recombinant Antihemophilic Factor Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Recombinant Antihemophilic Factor Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Recombinant Antihemophilic Factor Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Recombinant Antihemophilic Factor Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Recombinant Antihemophilic Factor Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Recombinant Antihemophilic Factor Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Recombinant Antihemophilic Factor Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Recombinant Antihemophilic Factor Sales Volume, (2025-2030) & (K Units)
    Table 57. Takeda Company Information
    Table 58. Takeda Introduction and Business Overview
    Table 59. Takeda Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. Takeda Recombinant Antihemophilic Factor Product Offerings
    Table 61. Takeda Recent Development
    Table 62. Bayer Company Information
    Table 63. Bayer Introduction and Business Overview
    Table 64. Bayer Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Bayer Recombinant Antihemophilic Factor Product Offerings
    Table 66. Bayer Recent Development
    Table 67. CSL Company Information
    Table 68. CSL Introduction and Business Overview
    Table 69. CSL Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. CSL Recombinant Antihemophilic Factor Product Offerings
    Table 71. CSL Recent Development
    Table 72. Pfizer Company Information
    Table 73. Pfizer Introduction and Business Overview
    Table 74. Pfizer Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Pfizer Recombinant Antihemophilic Factor Product Offerings
    Table 76. Pfizer Recent Development
    Table 77. Biogen Company Information
    Table 78. Biogen Introduction and Business Overview
    Table 79. Biogen Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Biogen Recombinant Antihemophilic Factor Product Offerings
    Table 81. Biogen Recent Development
    Table 82. Octapharma Company Information
    Table 83. Octapharma Introduction and Business Overview
    Table 84. Octapharma Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. Octapharma Recombinant Antihemophilic Factor Product Offerings
    Table 86. Octapharma Recent Development
    Table 87. Novo Nordisk Company Information
    Table 88. Novo Nordisk Introduction and Business Overview
    Table 89. Novo Nordisk Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Novo Nordisk Recombinant Antihemophilic Factor Product Offerings
    Table 91. Novo Nordisk Recent Development
    Table 92. Sanofi Company Information
    Table 93. Sanofi Introduction and Business Overview
    Table 94. Sanofi Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Sanofi Recombinant Antihemophilic Factor Product Offerings
    Table 96. Sanofi Recent Development
    Table 97. Sobi Company Information
    Table 98. Sobi Introduction and Business Overview
    Table 99. Sobi Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. Sobi Recombinant Antihemophilic Factor Product Offerings
    Table 101. Sobi Recent Development
    Table 102. Key Raw Materials Lists
    Table 103. Raw Materials Key Suppliers Lists
    Table 104. Recombinant Antihemophilic Factor Downstream Customers
    Table 105. Recombinant Antihemophilic Factor Distributors List
    Table 106. Research Programs/Design for This Report
    Table 107. Key Data Information from Secondary Sources
    Table 108. Key Data Information from Primary Sources
List of Figures
    Figure 1. Recombinant Antihemophilic Factor Product Picture
    Figure 2. Global Recombinant Antihemophilic Factor Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Recombinant Antihemophilic Factor Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Recombinant Antihemophilic Factor Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Recombinant Antihemophilic Factor Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Recombinant Antihemophilic Factor Report Years Considered
    Figure 7. Global Recombinant Antihemophilic Factor Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Recombinant Antihemophilic Factor Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Recombinant Antihemophilic Factor Revenue in 2023
    Figure 10. Recombinant Antihemophilic Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. 200IU Picture
    Figure 12. 250IU Picture
    Figure 13. Global Recombinant Antihemophilic Factor Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Recombinant Antihemophilic Factor Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Recombinant Antihemophilic Factor Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global Recombinant Antihemophilic Factor Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Recombinant Antihemophilic Factor Price by Type (2019-2030) & (USD/Unit)
    Figure 18. Product Picture of Hospital
    Figure 19. Product Picture of Pharmacy
    Figure 20. Global Recombinant Antihemophilic Factor Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 21. Global Recombinant Antihemophilic Factor Sales Value Market Share by Application, 2023 & 2030
    Figure 22. Global Recombinant Antihemophilic Factor Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 23. Global Recombinant Antihemophilic Factor Sales Volume Market Share by Application, 2023 & 2030
    Figure 24. Global Recombinant Antihemophilic Factor Price by Application (2019-2030) & (USD/Unit)
    Figure 25. North America Recombinant Antihemophilic Factor Sales Value (2019-2030) & (US$ Million)
    Figure 26. North America Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
    Figure 27. Europe Recombinant Antihemophilic Factor Sales Value (2019-2030) & (US$ Million)
    Figure 28. Europe Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
    Figure 29. Asia Pacific Recombinant Antihemophilic Factor Sales Value (2019-2030) & (US$ Million)
    Figure 30. Asia Pacific Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
    Figure 31. South America Recombinant Antihemophilic Factor Sales Value (2019-2030) & (US$ Million)
    Figure 32. South America Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
    Figure 33. Middle East & Africa Recombinant Antihemophilic Factor Sales Value (2019-2030) & (US$ Million)
    Figure 34. Middle East & Africa Recombinant Antihemophilic Factor Sales Value by Country (%), 2023 VS 2030
    Figure 35. Key Countries/Regions Recombinant Antihemophilic Factor Sales Value (%), (2019-2030)
    Figure 36. Key Countries/Regions Recombinant Antihemophilic Factor Sales Volume (%), (2019-2030)
    Figure 37. United States Recombinant Antihemophilic Factor Sales Value, (2019-2030) & (US$ Million)
    Figure 38. United States Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
    Figure 39. United States Recombinant Antihemophilic Factor Sales Value by Application (%), 2023 VS 2030
    Figure 40. Europe Recombinant Antihemophilic Factor Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Europe Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
    Figure 42. Europe Recombinant Antihemophilic Factor Sales Value by Application (%), 2023 VS 2030
    Figure 43. China Recombinant Antihemophilic Factor Sales Value, (2019-2030) & (US$ Million)
    Figure 44. China Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
    Figure 45. China Recombinant Antihemophilic Factor Sales Value by Application (%), 2023 VS 2030
    Figure 46. Japan Recombinant Antihemophilic Factor Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Japan Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
    Figure 48. Japan Recombinant Antihemophilic Factor Sales Value by Application (%), 2023 VS 2030
    Figure 49. South Korea Recombinant Antihemophilic Factor Sales Value, (2019-2030) & (US$ Million)
    Figure 50. South Korea Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
    Figure 51. South Korea Recombinant Antihemophilic Factor Sales Value by Application (%), 2023 VS 2030
    Figure 52. Southeast Asia Recombinant Antihemophilic Factor Sales Value, (2019-2030) & (US$ Million)
    Figure 53. Southeast Asia Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
    Figure 54. Southeast Asia Recombinant Antihemophilic Factor Sales Value by Application (%), 2023 VS 2030
    Figure 55. India Recombinant Antihemophilic Factor Sales Value, (2019-2030) & (US$ Million)
    Figure 56. India Recombinant Antihemophilic Factor Sales Value by Type (%), 2023 VS 2030
    Figure 57. India Recombinant Antihemophilic Factor Sales Value by Application (%), 2023 VS 2030
    Figure 58. Recombinant Antihemophilic Factor Industrial Chain
    Figure 59. Recombinant Antihemophilic Factor Manufacturing Cost Structure
    Figure 60. Channels of Distribution (Direct Sales, and Distribution)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Antihemophilic Factor Recombinant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Coagulation Factor Ⅷ for Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Antihemophilic Globulin Market Research Report 2024
Global Recombinant Coagulation Factor Concentrate Market Research Report 2024
Cryoprecipitated Antihemophilic Factor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Human Coagulation Factor VIII for Injection Market Research Report 2024
Plasma derived Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Human Coagulation Factor Ⅷ Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hemophilia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor von Willebrand Factor Complex Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Coagulation Factor VIII Market Research Report 2020
Coagulation Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Activated Coagulation Factor VII Market Research Report 2025
Global Recombinant Coagulation Factors Market Insights Forecast to 2030
Factor VIII Deficiency Treatment Market
Global Haemophilia Treatment Market Insights Forecast to 2030
Human Factor VIII Concentrate Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hemophilia Gene Therapy Market Research Report 2025

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions